Focus: Hikma is a specialty pharma company headquartered in Berkeley Heights, NJ, specializing in medication delivery across oncology, infectious disease, cardiovascular, neurology, and immunology. The company operates a portfolio of generic and branded products with significant revenue concentration in cardiovascular (Amlodipine Besylate at 34% of revenue).
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Hikma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (34% of company revenue) but post-patent with generic competition intensifying
Help build intelligence for Hikma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hikma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established immunosuppressive used in autoimmune disease with sustained Part D utilization
Oncology biosimilar in post-LOE phase facing competitive pressure from other biosimilar entrants
Branded colchicine with extended LOE to 2033; sole NDA product providing differentiation and patent protection
Generic colchicine for FMF in children; lower-value follow-on to branded MITIGARE
CNS stimulant NDA nearing loss of exclusivity; erosion expected as generic entry increases
GI anti-inflammatory post-LOE with multiple ANDA entries indicating competitive generic market
407 discontinued, 263 duplicate formulations not shown
+10 more products with revenue data
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
Six critical injectables on shortage list (Midazolam, Cefotaxime, Morphine, Dopamine, Furosemide, Fentanyl) flag potential manufacturing or supply-chain instability that may pressure operations and hiring stability.
+235 more products